Josh J Carlson

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 9

Top Topics

Metastatic Breast Cancer

St Segment Elevation Myocardial Infarction

Top Venues

PharmacoEconomics

American journal of cardiovascular drugs : drugs, devices, and other interventions

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Ashley Jaksa, Lisa Bloudek, Josh J Carlson, Kanya K Shah, Yilin Chen, Amanda R Patrick, Avery McKenna, Jon D Campbell
Key learnings from Institute for Clinical and Economic Review's real-world evidence reassessment pilot. International journal of technology assessment in health care 38 (1) (2022)
Kangho Suh, Josh J Carlson, Fang Xia, Todd Williamson, Sean D Sullivan
Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers. Journal of comparative effectiveness research 11 (14) (2022)
Kangho Suh, Anirban Basu, Josh J Carlson, Kelley R Branch
Exploring Medication Adherence with P2Y12 Inhibitors Using Conditional and Unconditional Quantile Regression Approaches. American journal of cardiovascular drugs : drugs, devices, and other interventions 21 (2) (2021)
Josh J Carlson, Gregory F Guzauskas, Robert A Dann, Scott D Ramsey
Budget impact analysis of the DiviTum TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer. Journal of medical economics 24 (1) (2021)
Nathaniel Hendrix, Deirdre Weymann, Jagori Chatterjee, Devender S Dhanda, Anirban Basu, David L Veenstra, Josh J Carlson
Provider preferences for resolving uncertainty and avoiding harms in precision medicine: a discrete choice experiment. Personalized medicine 17 (5) (2020)
Ang Li, Josh J Carlson, Nicole M Kuderer, Jordan K Schaefer, Shan Li, David A Garcia, Alok A Khorana, Marc Carrier, Gary H Lyman
Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States. Cancer 126 (8) (2020)
Josh J Carlson, Kangho Suh, Panos Orfanos, William Wong
Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer. PharmacoEconomics 36 (4) (2019)
Josh J Carlson, Shuxian Chen, Louis P Garrison
Performance-Based Risk-Sharing Arrangements: An Updated International Review. PharmacoEconomics 35 (10) (2018)
Josh J Carlson, David D Kim, Gregory F Guzauskas, Caroline S Bennette, David L Veenstra, Anirban Basu, Nathaniel Hendrix, Dawn L Hershman, Laurence Baker, Scott D Ramsey
Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study. Cancer medicine 7 (9) (2018)